Accelerating Excellence2008 the Official Publication of Bioscience in Ohio

Accelerating Excellence2008 The Official Publication of Bioscience in Ohio

Ohio Bioscience: The Image of Innovation

AE • also inside: Major company expansions | Cardio opportunities | Start-up upswing • AE AE • Accelerating 2008 Excellence The Official Publication of Bioscience in Ohio Published for: BioOhio (An Ohio Edison Center) 1275 Kinnear Road Columbus, OH 43212 (614) 675-3686 | Fax: (614) 675-3687 [email protected] | www.bioohio.com BioOhio President & CEO Anthony Dennis, Ph.D. Vice President John F. Lewis, Jr. Sr. Director, Workforce & Education William C. Tacon, Ph.D. Director, Corporate Communications Matt Schutte Director, Business Development Scott Osborne Executive Assistant Martie Hexamer Membership & Events Coordinator Jennifer Goldsberry Vice President, Finance & Administration William Poore Chief Operating Officer Robert A. Baxter

About BioOhio BioOhio is Ohio’s bioscience membership and development organization. A 501(c)(3) organization, BioOhio is committed to attracting and advancing bioscience organizations in Ohio through education, promotion, advocacy, engagement, and collaboration. Support for BioOhio is provided by the State of Ohio as well as BioOhio member organizations and sponsors.

Published by: BioMedia, LLC. Return Undeliverable Addresses to: 311 Lloyd Road / Cleveland, OH 44132 (216)373 -7676 | Fax (206)339-4452 [email protected] | www.ohiobiomagazine.com Editor-in-Chief: Matt Schutte Managing Editor: James O’Hare Intern: Keith Mokris Circulation & Research: Joyce McMahon

• AE Accelerating Excellence2008 The Official Publication of Bioscience in Ohio

MESSAGES: 7 Message from BioOhio President & CEO Anthony Dennis The Numbers Add Up in Ohio FEATURES: 10 The Image of a Prospering Bioscience Sector Ohio’s comprehensive strategy to nurture bioscience industry expansion is bearing fruit. 14 Communities Respond to Demand for Bioscience Workers An overview of bioscience workforce training programs that are making Ohio bioscience organizations more competitive and effective.

18 Growth Spurt As Ohio’s bioscience industry expands, major businesses are keeping pace. Facilities, communities, statewide and industry initiatives are expanding at growing rates, too.

21 Ohio, for Starters A quick survey of five bioscience start-ups illustrates that bioscience entrepreneurship thrives in Ohio.

25 Pumping Innovation Throughout the State The Global Cardiovascular Innovation Center marries big ambitions with big ideas.

IN BRIEF: 29 BioBriefs - Quick overviews of recent developments in Ohio. 33 BioOhio Member List Accelerating Excellence2008 From the Cover: The Official Publication of Bioscience in Ohio Dr. Chip Souba, Interim Senior Vice President for Health Sciences and Dean of The Ohio State University College of Medicine, and Dr. Michael Knopp, Director of the Wright Center of Biomedical Imaging, demonstrate the use of an

ultra-high-field 7 Tesla MRI scanner for use in Ohio Bioscience: The Image research to Ohio Governor Ted Strickland and of Innovation Lt. Governor Lee Fisher.

also inside: Major company expansions | Cardio opportunities | Start-up upswing

The Official Publication of Bioscience in Ohio AE • • AE Message from theMessage President from and the CEO of BioOhio President and CEO BioOhio Board of BioOhio of Trustees

Chairman Anthony Dennis, Ph.D. Timothy G. Biro Managing Partner, Ohio Innovation Fund General Partner, Reservoir Venture Fund Vice Chairman Mark Collar • $146 billion of direct and indirect economic output Chairman of the Third Frontier Advisory Board, State of Ohio

• 17.6% of Ohio’s Gross State Product Past Chairman Michael D. Hooven President & CEO, • 1.2 million Ohio workers, direct and indirect Enable Medical Technologies • 55 new companies started or attracted per year Members Jack A. Bantle, II, Ph.D. • $636 million in federal research grants Vice President for Research & Graduate Studies, Wright State University

• $128 million IPO Mark Coticchia Vice President, Research & Technology Management, Case Western Reserve University

f you guessed that these were Sandra Degen, Ph.D. I Vice President for Research, statistics related to Ohio’s University of Cincinnati automotive or aerospace industry, Anthony J. Dennis, Ph.D. you are mistaken. President & CEO, BioOhio

Paul DiCorleto, Ph.D. They are taken from BioOhio’s latest annual administration who continue the tradition of Chairman, The Lerner Research Institute of the “Ohio Bioscience Growth Report” describing advancing technology-based businesses in Ohio. Cleveland Clinic and Chairman, Department of Molecular Medicine, Case School of Medicine the state’s bioscience industry. Startled? Surprised? Incredulous? A lot of people are. This year’s edition of Accelerating Excellence John C. (Jack) Fisher highlights many aspects of both our Executive Vice President, But the data was produced independently and Ohio Farm Bureau Federation supports what BioOhio has been saying for governmental and private sector efforts, ranging from company formation and VC investments Peter G. Kleinhenz years. To quote former Governor Jim Rhodes, General Partner, CID Equity Partners “Ohio has more by accident than most states to established company expansions and the creation of innovative workforce training Barbara Kunz have by design.” Although seriously, most of President, Health and Life Sciences Global these results are not accidental, as you will learn programs. If you live in Ohio, you likely already Business, Senior Vice President, when thumbing through this magazine. know how exciting the environment in Ohio is Battelle Memorial Institute for the biosciences. Robert McGrath, Ph.D. In addition to our historical strengths, like Senior Vice President of Research, one of the best and most awarded hospital and But if you are flying over Ohio, perhaps on your The Ohio State University clinical networks in the country, the State of way to one of the coasts, consider stopping in James Rankin, Ph.D. for a day to learn a little bit more about Ohio’s Interim Vice President for Research, Ohio has invested aggressively in the biosciences Ohio University over the past five years. It has done so through dynamic bioscience and health care assets. the creative Third Frontier Project, its Edison John Rice, Ph.D. You just might decide to make this a regular Managing Partner, Centers (like BioOhio) and Edison Incubators, Triathlon Medical Ventures stop. AE the developing “Building Ohio Jobs” program, David R. Scholl, Ph.D. and the Ohio Research Scholars Program, President & CEO, Diagnostic Hybrids, Inc.

among several others. This unwavering James A. Scozzie, Ph.D. commitment is why the cover features Senior Vice President, BioEnterprise Governor Ted Strickland and Lt. Governor Lee Arnold W. Strauss, M.D. Fisher, the outstanding leaders of our current Professor & Chair of Pediatrics Director, Cincinnati Children’s Research Foundation

Accelerating Excellence AE • Looking for Deal Flow?

These companies are putting Ohio on the national venture investment map.

Companies receiving private investment since 2004

AcelleRx Ganeden Biotech STI Akebia Therapeutics Great Lakes Pharmaceuticals Symphony Medical American Safety & Health Health Pro Brands Synapse Biomedical Institute Hill Top Research Syncro Medical AMT Systems HTP Telerad Express AnalizaDx Icon Interventional Tolera Vertebration Aria Analytics Imalux Transcutaneous Technologies ViewRay Aris Teleradiology InfraRed Imaging Systems Treatment-on-Line WholeHealth Arteriocyte IntElect Trek Diagnostics WIL Research Laboratories AssureRx Interscopic Analysis Vascular Biogenics Workflow.com Athersys Interventional Imaging Ventaira Pharmaceuticals Xanthostat Atricure Laboratory Partners Avantec Life Line Screening Athersys AxioMed Spine MDG Medical (reverse merger) Ayalogic MemberHealth AtriCure Blue Chip Surgical Center Biomec Partners Merlot OrthopediX Cleveland BioLabs Calfacior Minimally Invasive Devices EdgePark Surgical Cardiac Power NanoStatics Eurand CardioInsight Technologies NCRx Optical HTP ChanTest (acquired by McKesson) NDI Medical

CH Mack uisitions Hygenic Neoprobe (purchased by CorTec)

Cleveland BioLabs q NextMed Systems Memberhealth

CleveX c Ogenix NDI Medical Click4Care Opticon Medical (product line alliance with partial exit) Copernicus Therapeutics Orthohelix RSB Spine Critisense (partial sale to Nuvasive)

P2D & A CryMed Sears Dental and Dental Care

Percuvision s CSF Therapeutics Trek Diagnostics PeriTec Biosciences (purchased by Magellen Biosciences) Danfoss AquaZ PetsDx Imaging USB Diagnostic Hybrids Phycotransgenics (purchased by Affymetrix)

DiraMed IPO’ Wellcorp PrognostiX Early Sense (purchased by Nationwide) Rescentris Excera SourceOne Healthcare Ricerca Biosciences (purchased by Merry) Franklin & Seidelmann hio Roscoe Medical Whole Health Management Fused Multimodality Imaging O (purchased by Walgreens) Simbionix Future Path Medical SpineMatrix

Just follow the money to Ohio www.BioOhio.com • AE www.bioenterprise.com www.biostart.com www.ohio.edu/biotech/ www.techcolumbus.org Looking for Deals? $846 Million Health Care Over 130 investment groups found Private Equity Investment Since great opportunities in Ohio. 2004

Core Network JumpStart Radius Ventures Cowan Healthcare Kadima Partners RA Capital Management Credit Suisse First Boston Kearny Venture Regional Commercialization Fund Crystal Ventures Kirtland Capital Reservoir Ventures Accel Partners Cystic Fibrosis Foundation Life Science Capital River Associates Accipiter Capital Management Custer Capital LSKW Investments River Cities Capital Funds Aisling Capital Danish Strategic Partners MB Venture Partners Riverside Capital Akron ArchAngels Network Deutsche Bank Securities MedEquity Partners RMS Investments Akron Radiology Group Development Capital Ventures Miami Valley Ventures Roulston Ventures Ampersand Ventures Docor Michael J. Fox Foundation RSL Investments Angiotech Domain Partners Morgenthaler Ventures Safeguard Scientific Astro Modeling Draper Triangle Ventures MPM BioEquities Scius (Spire Capital) Athenian Ventures DSM Venturing Mutual Capital SG Capital Partners Battelle Ventures DW Healthcare Partners NCIC Capital Siloam Biosciences Beecken Petty O’Keefe Early Stage Partners NCT Ventures Southern Ohio Creates Behrman Capital Entrepreneurs Fund New England Partners Companies BIOMEC ExOxEmis North Coast Angels Sterling Capital Biotechnology Value Fund Fidelity Biosciences Norwich Ventures Sun Bridge Partners Blue Chip Venture Company First Fifty Fund Nu Vista Partners Summit Health Ventures Blue Point Capital Fletcher Spaght Ventures Oak Investment Partners Summit Partners Boston Scientific Fort Washington Capital Oakwood Medical Investors Sunrise Equity Partners Partners Bridge Fund Ohio Tech Angel Fund Sycamore Partners Foundation Medical Partners Bridge Investment Fund OrbiMed Advisors Talisman Capital Frantz Medical Ventures Camden Partners Oxford Bioscience TechGenesis Fund Fusion Capital Fund Capital Resource Partners PA Early Stage Partners Teton Capital Glengary Ventures Case Technology Ventures Palo Alto Investors Thomas McNerney & Partners Greatbatch Charter Life Sciences Pappas Ventures Toucan Ventures Greylock Chrysalis Ventures Partisan Management TL Ventures Hambrecht + Quist CID Equity Partners Paul Capital Triathlon Medical Ventures Health Foundation Cincinnati Children’s Tomorrow Polaris Venture Partners U.S. Venture Partners Fund Innovation Works Pontifax Vivo Ventures CincyTech Invesco Funds Primus Venture Partners Welsh Carson Claritas Capital Investor Growth Capital Proseed Xgen Cleveland Clinic Innovations Isabella Capital Psilos Group Cogene Ventures James Richarson & Sons Queen City Angels

www.BioOhio.com www.bioenterprise.com www.biostart.com www.ohio.edu/biotech/ www.techcolumbus.orgAE • The Image of a Prospering Bioscience Sector

As he showed Mary the images of the tumor before surgery and the How Ohio plans to leverage a location after the surgery, Mary’s fears were eased by the vivid detail from the MRI, which revealed that no cancer cells were present. high-growth industry The pictures Mary saw were taken by an advanced imaging system developed by a collaborative research project between The Ohio State University and Philips Medical Systems with a significant research grant from the Ohio Third Frontier Project. The imaging techniques provide a novel way to evaluate cancer, determine if it is responding to therapy, and quickly determine if the disease remains in remission. In Mary’s case, the technique used is a combination of positron emission tomography (PET) and computed tomography (CT). When combined, PET/CT gives physicians a quantifiable, noninvasive assessment of tumor characteristics and biological activity. Prior to this development, surgeons could not clearly discern the boundaries of the tumor and, post-surgery, they could not see whether they had excised all cancer cells. Equally important, as illustrated in Mary’s case, they could not show the difference to their patients. That Mary now could see the results of her surgery gave her the reassurance she needed. Like Mary, we are able to view the dramatic progress made in bioscience development in the State of Ohio through the efforts of the Ohio Third Frontier Project. The successful track record of the state-funded Wright Center of Innovation in Imaging at The Ohio State University provides a vivid picture of Ohio’s strategic plan for creating jobs, and attracting new commerce and investments to spur the state’s competitiveness internationally. Governor Ted Strickland’s plan builds on the success of the Ohio Third Frontier, initiated in 2002, and will expand on the economic development goals forecasted and now starting to materialize. Although centered at The Ohio State University Medical Center in Columbus, the Imaging Center is a statewide collaborative endeavor By Marc Cloutier involving world-class university researchers working closely with industry researchers and commercialization experts. hortly after Mary regained consciousness from the anesthesia, Sher oncologist confidently assured her that the tumor had This collaboration brought together top scientists from The Ohio State been successfully excised. He had every reason to believe that all University, Case Western Reserve University, and Philips Medical Systems. cancerous cells had been removed. Yet despite this reassurance the The state’s investment of $17 million was matched with $35 million from oncologist detected doubt and apprehension in Mary’s eyes. By the three partners. In its four years of operation, the Imaging Center all accounts, her doubt was understandable; this was the second has attracted more than $23 million in additional research funding surgery Mary had undergone to remove a malignant tumor. and generated $76 million in sales. Pending orders for advanced MRIs Although the initial surgery had gone as well as could be expected, — manufactured in Philips’ Ohio plant — will more than triple sales in a number of cancerous cells that could not be detected had 2008. The Center has given rise to four new companies, creating a total remained in place, regenerating the tumor. of 116 high-wage jobs and retaining 191 jobs among the collaborating organizations. Twenty-one new patents have been filed. Following Mary’s second surgery, however, the oncologist had reason to feel more confident about his patient’s prognosis. The oncologist now The successful endeavors of the Wright Centers of Innovation and held in his possession a picture of the area where the tumor had been, other biomedical research and commercialization entities are serving and it showed in clear detail that all cancerous cells had been removed. as models for economic success. They are exemplified by Governor

10 • AE Strickland’s new economic “Jobs Stimulus Plan” and Ohio’s new Advanced and Renewable Energy ($150 million) - to create new Research Scholars Program. jobs by making Ohio a powerhouse of renewable and advanced energy production including wind, solar, and clean coal. Ohio’s blueprint for the future is based on experience that has yielded positive results. This experience has taught state leaders the following Additionally, the bipartisan economic stimulus plan will build on the axioms on which to guide the state’s technology-based economic state’s infrastructure and help local communities acquire the tools they development. Lieutenant Governor Lee Fisher, who also serves as the need to compete for economic development. A $1.02 billion investment Director of the Ohio Department of Development, summarizes the state’s would be directed in the following areas: strategy in two steps. Logistics and Distribution ($100 million) - to help spur job “First, basic university science is integral to the successful creation through investing in infrastructure that can be used to expand commercialization of scientific discoveries,” said Fisher. “It is the and support businesses that move and distribute products. Ohio’s star scientists who will provide the intellectual capital that defines central location in the nation makes it the preferred destination for a Ohio’s core technologies and determines its technological success. growing logistics and distribution industry. Growth of intellectual capital is the main attraction for new companies Local Infrastructure ($400 million) - to help build important and the expansion of established companies. Second, collaboration local infrastructure projects such as roads, bridges, sewers, and water between academic and corporate scientists has a significant effect systems. on performance measures and will drive our state’s economic development.” Clean Ohio Conservation ($200 million) - to help preserve farmland and greenspace. Ohio’s Jobs Stimulus Plan Clean Ohio Revitalization ($200 million) - to help revitalize our The economic development package initiated by Governor Strickland, cities and industrial areas by brownfield clean-up and transformation with strong bipartisan support from Ohio’s House and Senate into new residential and business development. leadership, will spur job creation throughout the state. This economic - to help revitalize stimulus plan provides significant investments in (1) new and emerging Historic Preservation Tax Credit ($120 million) historically significant buildings that, in turn, will expand the tax base of industries; (2) Ohio’s infrastructure; and (3) workforce and talent. the local community. The proposal’s investments of $1.57 billion will be funded through a combination of bond sales, existing revenue, and other sources. Finally, the economic stimulus plan will make critical investments in Ohio’s workforce and talent: Governor Strickland and state lawmakers are investing in Ohio’s competitive opportunities to support new and emerging industries. The Higher Education Workforce Initiative ($250 million) will The plan would make a $300 million investment in the following areas: keep more college-educated Ohioans in the state by linking them with good internships, cooperative education programs, and jobs while they Biomedical ($100 million) - to help create jobs through spurring a earn their degrees. Matched with private sector investments, this will part of Ohio’s economy that saves lives and leads to medical advances. make Ohio a leader in higher education and job creation efforts. While Bio-based Products ($50 million) – to help support and grow an the availability of high-quality jobs is essential to Ohio’s future, so too industry that aims to produce polymers, plastics, and other crucial modern materials out of Ohio-grown crops.

Gov. Strickland and Lt. Gov. Lee Fisher with the Imaging Center’s world-class team.

AE • 11 12 • AE are the investments we make to link Ohio students and Ohio graduates to those jobs. Moreover, attracting students and graduates back to Ohio is a critical component of this effort. Ohio’s Strategic Plan for Higher Education An innovative complement to the bipartisan Jobs Stimulus Plan is the Ohio Research Scholars Program. For 2008, this important program has made $150 million available to Ohio research universities to strengthen and increase Ohio’s number of clusters of research excellence. The effort is being led by Ohio’s academic institutions that support regional economic priorities. “The partnership creates an unprecedented and powerful collaboration between the Ohio Third Frontier Project and higher education,” Governor Strickland asserted. “This pledge reinforces our administration’s commitment to building on our existing strengths in research and technology to bring the best talent to Ohio, and keeping them here.”

Lt. Governor Lee Fisher visits InVasc Therapeutics’ lab at TechColumbus. From left, Dan Meek, Sanjay Rajagopalan, M.D., Madhavi Diwanji, Lt. Gov. Lee Fisher, Jun Liu, Ph.D., Rajagopal Desikan, Ph.D.

Ohio’s track record and future plans for the state’s vibrant technology-based economic development efforts have been lauded by several independent organizations. For the past two years Ohio has received the Governor’s Cup by Site Selection Magazine for leading the nation in new and expanded facilities. Ohio’s methodology for awarding development research grants and its overall approach to economic development was recognized by both the Pew Center on the States and the National Governors Association as a model for other states to emulate. Like Mary’s PET/CT images, Ohio’s picture of the future is clear and promising, according to Lt. Governor Fisher. “Ohio’s economic prosperity will be built around new ideas, products, and processes that capitalize on our existing assets and leverage new and emerging global opportunities. Many of these new products and processes are still in the research and development laboratories in Ohio companies, universities, and not-for-profit organizations. Many are the underpinnings of small, entrepreneurial Ohio companies. And many are in the early stages of development in companies outside of Ohio and the United States who will soon realize the economic advantages of relocating to Ohio for the economic and life-style advantages we offer.” AE

Marc Cloutier is the Ohio Department of Development’s senior advisor for biotechnology.

AE • 13 Communities Respond to Demand for Bioscience Workers

Workforce training programs attract state, federal funds

ith 800-plus bioscience-related organizations in Ohio—and Wmore arriving or launching every day—finding qualified talent can be a competitive endeavor for growing companies.

In a workforce survey conducted by BioOhio in spring 2007, the vast majority of respondents indicated their company was hiring, especially in the areas of R&D, quality assurance, and manufacturing. To broker connections between companies and prospective employees, several local and statewide bioscience workforce initiatives have come online in recent years, from first- time career fairs to strategic meetings between industry and academia. In December 2007, two separate projects were awarded significant public funds to develop future workers for bioscience-related industries. ‘Shape the future’ The BioScience Consortium of Northeast Ohio received a $500,000 planning grant to begin work on educational pathways such as medically-oriented sciences, devices and diagnostics, agricultural biotechnology, biomaterials and bioinformatics. The one-year grant was awarded by U.S. Rep. Ralph Regula, R-Navarre. Based in Ashland, Ohio, the seven-county consortium is composed “Space, equipment, and scheduling requirements necessitated our of nearly 30 businesses, educational providers and nonprofit investment in a lab that will meet the growing needs of this program,” organizations, including BioOhio. said Mike McDaniel, Ashland County-West Holmes Career Center “We truly thank Congressman Regula for this opportunity to shape the Superintendent. future in Northeast Ohio,” said Ashland Area Chamber of Commerce “It’s a fantastic complement and regional application of our statewide President Marla Akridge. “There is just no denying the correlation bioscience workforce efforts,” commented Bill Tacon, BioOhio senior between technology, education, and healthy economic development.” director of workforce and education. “Today, the commercial bioscience The consortium’s primary focus will be sector in Northeast Ohio contributes more than 15,000 direct jobs. We development of a new “Project Lead the Way” expect bioscience-related jobs to continue growing throughout the state, Tech Prep bioscience curriculum for 2008 with and that growth requires skilled talent.” the Ashland County-West Holmes Career Center. In addition to the Career Center’s BioScience Tech program, North Samaritan Regional Health System housed the Central State College will contribute to the consortium efforts by creating program in 2007, but Career Center officials are a “multi-skilled” bioscience program in which a cluster of academic using a portion of the grant to build a dedicated certificates will be offered on an intermittent basis. This flexible bioscience training lab in time for the 2008-2009 school year. A curriculum will allow students to develop technical competencies in a $500,000 investment from the local board of education will assist in variety of settings to meet changing market needs. Fellow consortium the renovation and relocation project. member Ashland University will develop additional targeted courses in 14 • AE the biosciences and offer continuing education workshops for area high school bioscience teachers. Other consortium partners, including Samaritan Regional Health System, the Ohio Agricultural Research and Development Center, and WIL Research, are offering student summer internships. Just-in-time training “Greater Cleveland and Ohio have become leaders in medical device and pharmaceutical drug development, manufacturing and distribution,” said Cuyahoga Community College President Jerry Sue Thornton. “By training more workers for this rising local industry, we will help grow a very bright sector of the region’s economy even further.” To help Cuyahoga Community College—commonly called Consortium Members to Date: “Tri-C”—meet that goal, the Ohio Board of Regents provided a $447,000 grant for the development of the Bioscience Workforce • Ashland County-West Holmes Career Center Training and Assessment Center, the first of its kind in Ohio. • Ashland City School District According to John Gajewski of the college’s workforce and • Aquarian Technology Systems, LTD economic development division, the center’s training programs • Ashland Area Chamber of Commerce will focus on three areas identified by regional employers as most • Ashland Area Council for pressing: medical device manufacturing; pharmaceutical drug Economic Development manufacturing; and regulatory and quality control training. • Ashland, Medina & Wayne Counties The Bioscience Workforce Training Center is located at Tri-C’s Ohio Farm Bureau Federation Unified Technologies Center in Cleveland. Programs began in • Ashland University June 2008 and will initially be offered to students and employees • BioOhio wanting to move into the pharmaceutical industry as entry level • Braintree (Edison Incubator) candidates. After successful implementation, Tri-C will then offer programs for incumbent worker training. • Cleveland Clinic Foundation – Wooster Nearly 65% of the companies responding to BioOhio’s 2007 • Clinical Research Management, Inc. workforce survey indicated they conduct training in-house, many • Crawford County Economic saying they were not aware of adequate external resources. Development Department • Delta Plant Technologies Bioscience jobs are among the 8,000 high-tech jobs in Northeast Ohio that are going unfilled, according to NorTech, the nonprofit • Detrow & Underwood economic development organization that focuses on high-tech • Lakeland Community College industries. • Medina County Works Given how important workforce development is to sustaining the • Mid-Ohio Educational Service Center growth of Ohio’s bioscience industry, BioOhio remains closely • Mid-Ohio Heart Clinic involved in both of these initiatives and others throughout the state. • North Central Consortium of Since speaking at the 2006 BioOhio Annual Conference, Russ Ohio College Tech Prep Read, director of the National Center for the Biotechnology • North Central State College Workforce, has advised BioOhio on workforce strategy and invited • Nortech its participation in pursuit of grants. • Ohio Agricultural Research and Development “BioOhio and their partners are on the right path,” Read said Center (OSU-Wooster) recently. “Given the U.S. biotechnology industry is growing at a • Ohio Department of Development double-digit rate and is regionally specific to employer needs, their • PolymerOhio, Inc strategy of connecting the supply side with the demand side makes a lot of sense.” AE • Samaritan Regional Health System • Stark State College of Technology • Tri-County Educational Service Center • WIL Research Laboratories, LLC

AE • 15 16 • AE AE • 17 Dublin-based Cardinal Health is in the midst of a $50 million expansion that will add 700 local jobs.

Growth Spurt The new west campus facility will house Cardinal Health’s Healthcare Supply Chain Services division, a $74 billion business that was formed through the combination of the company’s pharmaceutical and medical Major bioscience expansions in products supply chain divisions.

Ohio underscore growing industry At the groundbreaking, Ohio Gov. Ted Strickland said, “Cardinal Health is an inspiring example of Ohio’s entrepreneurial spirit. Growing from a s Ohio’s bioscience industry is expanding, so are major regional food distributor in 1971 to a global health care leader and the Acompany facilities and the jobs required to fill them. nation’s 19th largest company today, Cardinal Health is showing the way to Ohio’s economic renaissance.” According to a study released last December by BioOhio, the overall economic impact of Ohio-based bioscience was $146 The largest company in Ohio by revenue, Cardinal Health employs nearly billion in 2006, representing 17.6% of Ohio’s total economic 3,500 people across the state. With the completion of the new facility, output. Bioscience also directly and indirectly sustained 1.2 slated for spring 2009, the company will add more than 700 additional million jobs in Ohio that year. jobs in Dublin.

By including three integrated sectors—commercial bioscience Ohio two step entities, hospitals and healthcare providers, and medical colleges— BioOhio’s definition of the bioscience industry may be considered Fresh off a 2006 announcement to build its first-ever manufacturing plant, broad. However, even the state’s commercial bioscience sector Amylin Pharmaceuticals announced last May the expansion of that plant alone accounted for a $27.3 billion overall economic impact and being built in West Chester, a northern suburb of Cincinnati. The $400 48,485 direct jobs in 2006. When indirect and induced jobs are million expansion is expected to result in the creation of up to 500 jobs factored, the commercial bioscience employment figure jumps to over the next three years. 128,206.

Already impressive, these statistics undoubtedly will increase with a relatively silent, but impressively steady, string of major bioscience company expansions in all corners of the Buckeye State.

Flying high In October 2007, Cardinal Health broke ground on a $50 million, 250,000 square foot expansion of its Dublin, Ohio, headquarters. Cardinal Health is an $87 billion company providing products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients.

President & CEO Daniel Bradbury describes Amylin’s expanding West Chester facility to Gov. Strickland and Lt. Gov. Fisher. 18 • AE The site is being designed to manufacture exenatide long-acting release receiving regulatory approval. Ben Venue currently employs nearly 1,200 (LAR), a diabetes drug candidate currently in clinical development, people. Company officials expect to hire an additional 150 to 200 people and full build-out is dependent on continued progress of exenatide LAR within two years of the new facility’s completion. through its development process. Amylin already manufactures a twice- daily formulation of the drug under the brand name Byetta. Bricks & mortar for R&D “Amylin’s Ohio manufacturing facility is an important investment in our In 1985, specialty pharmaceutical company Eurand, based in Milan, Italy, mission to deliver life-changing medicines to the patients we serve,” said opened its U.S. operations in Vandalia, near Dayton. On September 27, Amylin Pharmaceuticals President & CEO Daniel Bradbury. “We believe 2007, the company broke ground on a 13,000 square foot expansion Ohio has a favorable business environment and is an ideal location for to its 90,000 square foot research and manufacturing facility. The $5.5 investing in our company’s future growth.” million investment also will include renovations in portions of the existing building. Completion is expected in 2009.

More square feet for more employee feet (continued) Upon receiving a 55%, 5-year job creation tax credit from the State of Ohio last December, Charles River Laboratories announced their decision to build a 58,000 square foot addition to its pre-clinical development facility in Spencerville.

A global provider of services and solutions that accelerate the drug discovery and development process, Charles River currently operates over 50 facilities in 15 countries worldwide.

The $16 million investment in Ohio will add 80 new jobs to the current workforce of 200 over the next three years. According to company officials, construction is expected to be complete by mid-2009.

In addition to Ohio, Charles River considered Massachusetts, Nevada, and Quebec, Canada, for this expansion, three of six areas worldwide where Charles River has either completed new construction or is currently expanding existing plants.

21st Century growth It seems that for much of the past decade, Bedford-based Ben Venue Laboratories has been in expansion mode. Ben Venue is part of the Boehringer Ingelheim group of companies and a leading producer of sterile injectable pharmaceutical products.

The company started construction last July on a $71.5 million addition to an unfinished $67 million building. The new 244,000 square feet plant will be devoted to the production of cytotoxic and genotoxic compounds used in cancer treatments. To prevent toxic drugs from contaminating nontoxic drugs, the new plant is isolated from other Ben Venue operations.

The expansion is scheduled to be completed by the end of 2008 and production will begin upon

AE • 19 Eurand develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. In May 2007, Eurand successfully launched an initial public offering of 7 million ordinary shares priced at $16 a share. The stock trades on NASDAQ under the symbol EURX.

“The expansion of our Vandalia facility will allow us to continue to provide innovative products to our current customer base while broadening our U.S. presence,” said Eurand CEO Gearóid Faherty. “This project underscores our commitment to research and development as a critical component of our future success.”

WIL’s power Eurand Chief Commercial Officer John Fraher Like Charles River Labs, WIL Research Laboratories is benefiting from the and BioOhio’s Tony Dennis at Eurand’s expansion recent surge in pharmaceutical R&D outsourcing. A non-clinical contract groundbreaking last September. research organization based in Ashland, WIL Research opened the third and last phase of a major expansion project in November 2006. The new facility added 52,000 square feet of vivarium and new state-of-the-art bioanalytical, analytical and metabolism labs.

The $34 million construction project, which began in 2005, totaled 100,000 square feet. The project is expected to create 80 new jobs and maintain 500 at the project site within the first three years.

Fast company One of the fastest growing pharmaceutical companies in terms of relative growth and prescriptions, Prasco Pharmaceuticals will move to a new headquarters in Mason, Ohio, in July 2008. The company has successfully launched the largest number of authorized generics in the industry.

The new 28 acre campus includes 90,000 square feet of administrative offices, an 8,000 square foot multimedia auditorium, and an additional 70,000 square foot warehouse expansion. Always an eager and generous contributor to their community, the company also is building Prasco Park—a premier baseball diamond for select amateur baseball in the Midwest—on their new campus.

These examples underscore and contribute to the overall growth of Ohio’s bioscience industry. With $100 million in support from a bipartisan jobs stimulus package, the likelihood of even more bioscience company expansion is, well, expanding. AE

20 • AE Ohio, for Starters

Bioscience entrepreneurs discover the Midwest’s launch pad

t’s a fact: Ohio isn’t perceived by the rest of the world as a Ibastion of bioscience and biomedical entrepreneurship. Even though this is a magazine written, designed and published by Ohioans, we’re okay with that statement appearing in print. But we’re also motivated to challenge that perception with reality.

Many in this business—including some Ohioans—associate “bioscience in Ohio” with global brands and massive companies with headquarters in Ohio. Organizations like Battelle, Cardinal Health, Cleveland Clinic, P&G Pharmaceuticals, STERIS, Abbott Nutrition, Invacare, and so on. That’s not a bad thing. It’s just not CleveX’s handheld ExiClip device a whole story thing.

From 2004 to 2007, an average of 55 new bioscience-related companies began operation in Ohio each year. A few were relocations from other states or countries, but most were started by—wait for it—entrepreneurs in Ohio. They started their companies here and were quickly surrounded by resources to help Jankowski is quick to point out that expertise and resources available in them succeed, from incubators and networking groups to private their backyard have contributed to Polgenix’s early success. “Relationships equity sources and legal expertise. with both Case Western Reserve University and BioEnterprise have been invaluable, particularly in allowing us to so quickly ramp up after launch,” Rather than continue with more stats and figures that support he said. Ohio’s entrepreneurial climate, let’s introduce you to just a few of Ohio’s emerging bio-stars. Asked what Polgenix might look like in five years, Jankowski has double vision. He forecasts both a pharmaceutical service company engaged in Polgenix myriad developmental partnerships and a VC-backed device company developing retinal imaging technologies. Launched in 2006, Polgenix’s vision is all about the eye. The Cleveland company is engaged in drug discovery and diagnostic development based on scientific discoveries CleveX related to the retina’s Skin cancer is the most common form of cancer in the U.S. According to function. Their research CleveX President & CEO Gary Smith, every year over 6 million skin lesions efforts are focused on are excised and biopsied in this country alone. Therein lie the target high-value and clinically-important G protein-coupled receptors. market for CleveX and the benefits of their technology. Simultaneously, they’ve devised novel instrumentation that provides safe, Columbus-based CleveX creates and markets innovative skin biopsy, real-time, in vivo imaging of the human eye’s functional components. closure and repair technology that enables clinicians to more quickly Founder Krzysztof Palczewski, currently chair of Case Western Reserve diagnose and treat skin cancers, University’s Department of Pharmacology, is the inventor of the discoveries including melanoma. The company’s and patents underlying each platform. Thus far, Polgenix has been funded ExiClip, a small device that removes through SBIR awards and partnerships with pharmaceutical companies. skin lesions and closes the site in According to CEO Joe Jankowski, the funding supports eight employees, a single action, received 510(k) five of which are full-time. clearance in May 2007.

AE • 21 The ExiClip idea was location even helped it land a grant from the Cleveland-based Global conceived by co-founder Cardiovascular Innovation Center. Jill Banbury, a plastic surgeon formerly affiliated PrognostiX with the Cleveland Clinic. A 2004 start-up based on Cleveland Clinic Co-founder Warren technology, PrognostiX discovers, develops, Williamson, also founder and commercializes proprietary molecular and president of Cincinnati’s biomarkers that aid in disease diagnosis and IDx Medical, translated the treatment. Within just a couple years, its first idea into a product. product—CardioMPO—had received FDA CleveX’s progress to date has been funded by seed and founder approval and was on the market. investments, as well as angel investors, namely Ohio TechAngels. Smith The ELISA-based CardioMPO Test measures myeloperoxidase (MPO) anticipates a B-round of VC funding, between $3 million and $5 million, levels in human plasma and helps clinicians evaluate patients presenting in early 2009. with chest pain that are at risk for major adverse cardiac events, including Smith said the company also has received timely and coordinated support heart attack or need for revascularization. PrognostiX also has a number from TechColumbus, BioOhio, BioEnterprise, CCF Innovations, and the of other novel biomarkers in the R&D pipeline. Ohio Department of Development. “Locating in Ohio was a natural fit, as the technology was licensed out of “Starting a company is a contact sport,” he said, by way of double the Cleveland Clinic,” said President & CEO George Trutza. “With offices entendre. “Our friends and advisors from TechColumbus, BioEnterprise, on the Clinic’s CCF Innovations campus, we can take advantage of all their and BioOhio have allowed us to establish far more key contacts with resources, such as access to world class researchers and clinicians.” business partners and investors than would have been possible by ourselves.”

Akebia Therapeutics With two drug development programs licensed from Procter & Gamble Pharmaceuticals, CEO Joseph Gardner said the company’s origin can be traced to P&G’s 2006 decision to discontinue internal drug discovery efforts in order to focus on licensing later-stage product candidates. Soon thereafter, in February 2007 Cincinnati-based Akebia Therapeutics started business.

Akebia is a venture-backed company with a focus on treatments for anemia and peripheral artery disease. Currently pre-clinical, the company’s therapies are at least five years from market. Dr. Gardner, who formerly managed medicinal chemistry, core technologies and intellectual property at P&G Pharmaceuticals, heads up Akebia’s full-time staff of six.

The company’s seed round was funded by national and local investors, including Triathlon Medical Ventures, Blue Chip Venture Company, CincyTechUSA, Fort Washington Capital, and Queen City Angels. Closure of an A-round involving three additional VCs will be announced in early summer.

Gardner said that locating in Cincinnati made sense, “considering the P&G connection, and it has facilitated valuable relationships with nearby contract research partners like Girindus and CTI.” Akebia’s Ohio

22 • AE Although several years away from having a commercial cancer drug, Bexion expects to market a preclinical tumor diagnostic imaging reagent this year. Takigiku said that the company has benefited from a multi-disciplinary support network. Its scientific advisory board and board of directors, as well local bioscience incubator BIOSTART all have contributed to Bexion’s successful start.

Different targets. Different stages of progress. Different paths. But each of these companies contributes to the proof that Ohio knows how to rear its young bioscience companies. AE

PrognostiX launched with funding via grants and angel investors. And with Cleveland Clinic, Case Western Reserve University, and several other major We GROW research institutions in northeast Ohio, Trutza said that finding employees has never been a problem. Great bio Ideas in Cuyahoga County!

Cuyahoga County has a variety of programs that Bexion Pharmaceuticals promote business growth Founded in Cincinnati in June 2006, Bexion including: Pharmaceuticals is focused on a goal everyone can agree on: developing cures for cancer. Bexion has a first-in-class biologic product with data-driven •New Product Development potential for treatment of a broad range of human & Entrepreneurship Program cancers.

“Our initial interests are gliomas and prostate •Cuyahoga Innovation Zones cancer,” commented President & CEO Ray Takigiku. “Our technology has rescued mice with gliomas, •Grow Cuyahoga County Fund where no other therapies have previously worked, and we have a remarkably good safety profile.”

Three full-time staff are charged with commercial- For more information about our award winning programs and how we can make izing the technology invented by Dr. Xiaoyang Qi and a Cuyahoga County location work for you, licensed from Cincinnati Children’s Hospital Medical talk to us. Center. Seed funding came through the Tomorrow Fund, a Cincinnati Children’s owned and operated investment fund, and a Phase 1 SBIR grant. Bexion Cuyahoga County is currently seeking Series A funding to complete the Department of Development 112 Hamilton Court, 4th Floor IND and Phase 1 clinical trial. Cleveland, OH 44114 P: 216-443-7260 F: 216-443-7258 www.development.cuyahogacounty.us

AE • 23 24 • AE Pumping Innovation Throughout the State

The Global Cardiovascular Innovation Center and the Next Big Ideas

ou have a diagnostic test or new medical device that could Ohio. In addition, the center will construct a facility that will have the Ypotentially improve care for patients suffering from heart ability to house up to 20 startup cardiovascular firms. Located close to disease. Now what? the heart of the Cleveland Clinic research and clinical operations, the center will provide the proximity and links to ensure that translational A wise first step would be contacting the Global Cardiovascular Innovation research moves rapidly from preclinical studies to early- and late-phase Center (GCIC), a state-wide catalyst for cardiovascular innovation. The clinical trials, and on into clinical practice. The GCIC is also working with GCIC specializes in commercializing innovations like these, propelling incubators and accelerators around the state to house GCIC companies. them to market quicker so that patients can benefit sooner. Mark Low, managing director of the GCIC, said the consortium partners Founded in 2007, GCIC is a $250 million product commercialization are committed to establishing Ohio as one of the premier locations for consortium made possible by a $60 million grant from the State of Ohio’s cardiovascular businesses, both new and established firms. Third Frontier Project. It’s the largest-ever grant made under the Third Frontier Project, the state’s billion dollar effort “We’re aiming to provide the complete array of factors to expand Ohio’s high tech research capabilities, that cardio businesses need to grow,” he said. “An promote innovation and create high-paying jobs. environment that provides unparalleled access to researchers, mentors and development expertise, On top of developing and acquiring new low-cost and flexible incubator space, core technologies, the GCIC also looks to launch facilities for rapid prototyping and development, new companies and recruit companies world class preclinical and clinical testing, and experienced executives to establish and connections to a strong supply and an internationally recognized cluster of manufacturing infrastructure.” cardiovascular expertise in Ohio. In his 2008 State of the State Address, In addition to facilitating the formation of new Ohio Governor Ted Strickland commended companies, the GCIC team has been working the public-private partnership formed to with companies from around the U.S. and from develop new cardiovascular products. “It will Brazil, France, Hungary, Ireland, and Israel to help create hundreds of new jobs,” he said, “and more them establish operations in Ohio. The overall goal of importantly, it will help countless patients in Ohio and the GCIC to is create or attract 40 companies and create 850 around the world overcome a terrible threat to their health.” related jobs by 2011. Already, four cardiovascular companies have located in Ohio to access GCIC experts, funds, and partners. This independent consortium is led by the Cleveland Clinic, the nation’s top heart care center for 13 years running, and includes an enviable GCIC also assists institutions and companies by providing resources and cast of industry and clinical partners—AstraZeneca, Boston Scientific, funding for technology commercialization. In a short time, GCIC already IBM, Johnson & Johnson, Medtronic, Procter & Gamble, Siemens, Case has held two rounds of funding during 2007, allocating $6.5 million to the Western Reserve University, the Ohio State University, the University of development and commercialization of 27 cardiovascular technologies, Cincinnati, the University of Toledo and University Hospitals of Cleveland. including groundbreaking imaging techniques, cellular therapies, and It is also strategically linked to economic development partners, including vascular devices. Funding recipients include Akebia Therapeutics, BioOhio, BioEnterprise, Fairfax Renaissance Development Corporation Interventional Imaging, and ZIN Medical, among other emerging and TeamNEO. companies. Nearly $30 million of the $60 million provided by Ohio’s Third Frontier Some of Ohio’s leading research institutions also have attracted GCIC Project will be used to provide seed funding for start-up companies. investment. The Ohio State University received funding to further develop To receive funding, the companies need to have a physical presence in electrostatic spinning of biodegradable nanofibers. Case Western Reserve

AE • 25 University will use funds for glycoprotein inhibitor R&D and a non- Estimated at over $420 billion, cardiovascular medicine is the largest embryonic stem cell network. The Cleveland Clinic received grants for health care market opportunity in the U.S. The cardiovascular disease projects including neuroactive stents and mitral annular remodeling. And burden poses clear challenges—medical, scientific, and commercial. the University of Toledo earned financial support for ongoing drug design “As the leading cause of death in the U.S., heart disease represents an area and development efforts. of vast opportunity for the development of life-saving technologies and “With more than 100 cardiovascular-related entities already in Ohio, we procedures,” said Delos M. “Toby” Cosgrove, M.D., CEO and president have an exciting and existing, albeit unrecognized, cluster,” said Tony of Cleveland Clinic. “By establishing an internationally recognized center Dennis, president and CEO of BioOhio, the state’s bioscience membership that unites the most advanced research, clinical care, talent and medical and business development organization. breakthroughs, the GCIC intends to maximize such opportunities, significantly improving the economic landscape of our community and “We are excited that with the GCIC, Ohio’s reputation will quickly transforming patient care.” become known as the cardiovascular destination for innovative, growing companies,” he added, “and our $146 billion bioscience economic Cardiovascular research and commercialization as well as millions of impact will continue to rise.” patients around the world soon will benefit from the progress made through companies and technologies affiliated with Ohio’s Global Cardiovascular Innovation Center. For more information and the current funding RFP go to www.GCIC.org. AE

GCIC Project Funding 2007

# of funded Category projects Vascular Devices 5 Drug Development 4 Blood Pumps 1 Stem Cell 5 Diagnostics 3 Valve Products 3 Ambulatory Monitoring 1 Imaging 3 Medical Food 1 Surgical Products 1

26 • AE In profound gratitude for all that Ohio Bioscience professionals do to help find a cure for breast cancer: Thank You, Ohio! In 2007, Susan G. Komen for the Cure funded seven research grants in Ohio totaling $1,668,722. Susan G. Komen Northeast Ohio Race for the Cure® Susan G. Komen Northwest Ohio Race for the Cure® Cleveland – September 13, 2008 Toledo – September 28, 2008 Locally presented by: University Hospitals Ireland Cancer Center Locally presented by: Northwest Ohio Ford Dealers

Susan G. Komen Greater Cincinnati Race for the Cure® Susan G. Komen for the Cure Columbus Pink Tie Ball® Cincinnati – September 14, 2008 Columbus – October 17, 2008 Locally presented by: Kroger Susan G. Komen Columbus Race for the Cure® Columbus – May 16, 2009

AE • 27 4 questions: 1 answer: ■ Subscription info? ■ Order Reprints? ■ ohiobiomagazine.com ■ Access past issues? ■ Learn how to put the bioscience +1.216.373.7676 audience to work for you?

28 • AE Bio Briefs

August, 2007 BioOhio’s comprehensive definition of the bioscience industry includes three integrated sectors: commercial bioscience entities, hospitals and International attendees crowd healthcare providers, and medical colleges. The commercial bioscience Stem Cell meeting sector alone accounted for a $27.3 billion overall economic impact and Over 300 attendees from 27 countries participated in a Center for Stem 48,485 direct jobs in 2006. The commercial bioscience employment Cell and Regenerative Medicine (CSCRM) meeting held in Cleveland, figure jumps to 128,206 when indirect and induced jobs are factored, Ohio. The Adult Mesenchymal Stem Cells in Regenerative Medicine For the complete report and appendix, visit: Conference accepted 100 abstracts and brought together 127 different www.bioohio.com/growthreport07.pdf world-wide institutions.

CSCRM also has helped organize RENEW (the Regenerative Medicine Education Network), a global collaboration of stem cell research December, 2007 centers in the U.S., England, Ireland, Belgium, Israel, Australia, and Ohio attracts major Singapore focusing on instruction and research in regenerative bioscience-related events medicine. Worldwide videoconferencing of classes begins in Autumn 2008. In addition to the events delivered by BioOhio and its members, 2008 sees several “national” events coming to Ohio.

November, 2007 The Association of University Technology Managers (AUTM) Central Region Meeting – Cleveland, July 14-16; meeting hosts Ohio Bioscience Career Fair 200 technology transfer professionals attracts and impacts The 40th Central Region Meeting of the American Chemical Society (CERMACS) – Columbus, June 10-14; more than 1,200 200 job seekers mingle with 21 recruiting companies attendees, including students, academics, and business professionals BioOhio hosted its 2nd Annual Ohio Bioscience Career Fair in from throughout the Midwest. Columbus. Nearly 200 job seekers, from current students to industry 12th Annual State Science Technology Institute (SSTI) veterans, benefited by meeting with 21 company exhibitors, including Conference – Cleveland, October 14-16; host sponsor is NorTech Alkermes, Amylin, Battelle, Ben Venue Labs, Diagnostic Hybrids, Eurand, for the conference offering opportunities for tech-based economic NAMSA, and WIL Research. Attendees traveled to Columbus from cities development practitioners and policy makers to further their throughout Ohio, including Cleveland, Cincinnati, Toledo, Akron, professional development and learn how to apply best practices to and Dayton. To date, exhibiting companies report that more than 40 their situation. interviews and at least seven new hires have resulted from this event. National Career Pathways Network 2008 Annual Conference – Based on positive feedback and results, BioOhio plans on continuing the Cincinnati, October 22-25; theme is “Connecting for Success: annual statewide career fair and is also considering regional offerings. Building the Future Talent Pipeline,” and programming includes bioscience-centric sessions. Organizers expect over 3,000 attendees. December, 2007 Ohio bioscience and healthcare economic impact near $150 billion More than 800 bioscience-related entities counted in the state A report released by BioOhio indicated the growing importance of bioscience to the state’s economy. The overall economic impact of Ohio- based bioscience was reported at $146 billion, representing 17.6% of Ohio’s total economic output. Bioscience also directly and indirectly sustained 1.2 million jobs in Ohio as of 2006.

AE • 29 February, 2008 The Ohio Supercomputer Center will partner with the Ralph Regula School of Computational Science, Ohio University, 11 other colleges and Investors nudge biotech firm ViewRay to universities, and industry leaders to attract and graduate an estimated move to Cleveland 345 students in STEM fields over a five-year period. Heavy-hitting investors on the East and West coasts offered ViewRay a $25 million investment to speed development of its medical imaging and treatment device. April, 2008 But there was a catch. To get the money to continue its product NE Ohio experts collaborate on novel development, the company had to move from Gainesville, Fla., to a diabetes research center of bioscience innovation. The investors suggested a handful of places. Artificial pancreas concept employs multidisciplinary, cross-organizational approach Would it be Boston? San Francisco? North Carolina’s Research Triangle? Atlanta? Nope. The company picked Greater Cleveland. At the American Chemical Society national meeting in New Orleans, a team consisting of members from three Cleveland-area organizations For the complete article, see www.bioohio.com. presented an intriguing approach to treating diabetes. Chemistry, polymer science, microbiology and immunology researchers are collaborating with surgeons and clinicians on what is being called a February, 2008 bioartificial pancreas. Midwest health care startups raise record The potentially breakthrough medical device represents the work of a $1.2 billion in 2007 team consisting of members from the University of Akron, the Cleveland Clinic, and the Northeastern Ohio Universities College of Medicine. Minnesota and Ohio attract most dollars Next steps involve further animal experiments to build upon successful Midwest health care startups attracted a record $1.2 billion in new preliminary findings. investments in 2007, according to the Midwest Health Care Venture The collaboration is being led by: Investment Report released by BioEnterprise, a BioOhio regional affiliate. The total represents a 55% increase over 2006, a sharp rise • Dr. Joseph Kennedy, professor of chemistry and polymer science, that both outpaces national venture industry growth and even surpasses University of Akron the 25% increase that occurred in the previous year. • Dr. Ken S. Rosenthal, professor of microbiology and immunology, “The rise of Midwest health care ventures has accelerated in an almost Northeastern Ohio Universities College of Medicine exponential manner,” said Baiju R. Shah, president of BioEnterprise. • Dr. Sharon F. Grundfest-Broniatowski, a surgeon with the Cleveland “The pipeline of high-quality ventures continues to both mature and Clinic Foundation gain greater national venture interest.”

May, 2008 March, 2008 Ohio Capital Fund marks OSC to Power ‘Choose Ohio First’ new investment milestone Bioinformatics Program Infusions from a state-backed venture-capital investment fund are Consortium garners $4.475 million in state funding approaching the $100 million mark after the Ohio Capital Fund identified another $25 million in awards. A proposal led by Ohio University and powered by the resources of the Ohio Supercomputer Center and the Ralph Regula School of The fund has a total of $150 million authorized for investment. The four Computational Science helps position Ohio as a national leader in the latest investments total about $25 million, and will be awarded to VC emerging field of bioinformatics. funds in the life sciences and information technology sectors. The Ohio Capital Fund is one aspect of statewide initiatives to push investments in Among seven projects to earn funding in the first round of the new the state’s emerging technology businesses. Choose Ohio First scholarship program, the Ohio Consortium for Bioinformatics will receive $4.475 million from the Ohio Board of Regents for student scholarships. The seven successful proposals announced — of 28 submitted — will receive more than $22.7 million for student scholarships in science, technology, engineering, mathematics and medical (STEM) fields.

30 • AE May, 2008 “Our goal is to recruit in 40 or 50 medical trade shows to the hall,” said State awards $143 million for tech research, Mark Falanga, senior vice president of commercialization Merchandise Mart Properties. Falanga A collection of 10 technology-focused research initiatives at institutions pointed to the “great access to great people throughout the state are poised to implement awards totaling over within the medical infrastructure that exists $143 million from the State of Ohio. The money comes from the Ohio in Cleveland” and estimates that the influx Research Scholars Program. As part of the award, recipients will be able of investment will have an approximately to recruit talent and provide facilities for 26 senior researchers. The $1 billion annual effect on the Ohio research will focus on multiple high tech areas, with most in bioscience- economy. related disciplines such as advanced materials, bio-imaging, spinal Mark Falanga implants and other basic and applied research. It also will be used for collaborations focused on those lines of research. The program is part of the Ohio Third Frontier Project, a $1.6 billion effort designed to use high-tech investments to spur the state’s economy. “These projects exemplify the unbreakable link between economic development and higher education that is critical in developing not only groundbreaking research but product commercialization,” said Ohio Lt. Governor Lee Fisher, who also serves as Director of the Ohio Department of Development. The following institutions received funding: • University of Akron • Bowling Green State University • University of Cincinnati • Cleveland State University • University of Dayton • Miami University • Northeastern Ohio Universities College of Medicine • Ohio University www.ohiobiomagazine.com • The Ohio State University • University of Toledo Accelerating • Wright State University Excellence2008 The Official Publication of Bioscience in Ohio May, 2008 Medical Mart in development in Cleveland Chicago-based Merchandise Mart Properties is teaming with Cuyahoga County, the Cleveland Clinic and other Cleveland-area medical and healthcare suppliers to develop and operate the Medical Mart. A collection of permanent showrooms as well as an accompanying trade show and meeting center are expected for a downtown Cleveland Ohio Bioscience: location. Site selection is slated for the summer of 2008. The Image The project is still in the early planning stages. When complete, the of Innovation Medical Mart is expected to cost about $400 million, and include 100,000 sq. ft. of showroom space, 300,000 sq. ft. of trade show space and a conference center. also inside: Major company expansions | Cardio opportunities | Start-up upswing

AE • 31 32 • AE Founding Members Battelle | Case Western Reserve University | The Cleveland Clinic | Ohio University | The Ohio State University | Procter & Gamble Pharmaceuticals | University Hospitals of Cleveland | University of Cincinnati Pillar Members Abbott Nutrition | Cincinnati Children’s Hospital Medical Center | Diagnostic Hybrids | Ethicon Endo-Surgery, Inc. | Nationwide Children’s Hospital | PhRMA | University of Toledo | Wright State University Member Organizations AccuNet, Inc. Columbus State Community College Ingenuity IEQ RAPID MR International, LLC Activaero America, Inc. Compliance Associates Integrated Bioscience Solutions REA Incorporated Aetion Technologies LLC CompuSniff LLC Integrated DNA Technologies RelayHealth Akron General Medical Center Copernicus Therapeutics, Inc. Interplex Medical, LLC Remedy Compensation Consulting Alkermes Corky Thacker Communications, Inc. InVasc Therapeutics Rescentris, Ltd. Amgen CTI Clinical Trial and Consulting Jacobs Carter Burgess Reservoir Venture Partners Amylin Ohio, LLC Services Kelly Scientific Resources REU Associates Inc. Analiza, Inc. Cuyahoga Community College Kforce Scientific Ricerca Biosciences Aniara Corporation Delp & Associates, LLC KGM Innovation Associates, Inc. Sales Force 4 Hire Applied Biomolecular Technologies Denville Scientific, Inc. Lakeland Community College Schottenstein, Zox & Dunn Co., LPA ATECH Detrow & Underwood LeadScope, Inc. Siemens Building Technologies AtriCure Corporation DiaPharma Group, Inc. Leff & Associates Sigma-Aldrich AxioMed Spine Corporation DIRAmed, LLC Leis Medical, Inc. Simbionix BCC Group LLC Drug Discovery News LexaMed, Ltd. Sinclair Community College Bedford Laboratories, Inc. Edison Biotechnology Institute MAR-TEST, Inc. Sound Health, Inc. Ben Venue Laboratories EF Scientific, LLC McNeal Enterprises, Inc. Sparton Medical Benesch, Friedlander, Coplan & ElectroSonics Medical Inc. McNees Wallace & Nurick, LLC Squire, Sanders & Dempsey LLP Aronoff LLP Enlyton, Ltd. Media II, Inc. STATKING Consulting, Inc. Bexion Pharmaceuticals EnteraTech Inc. Meridian Bioscience, Inc. STERIS Corporation Biedenbach & Stein, Inc. Eurand Molecular Research Center, Inc. Stratagene BIO/START Fertility Solutions, Inc. Mork Process, Inc. Strategic Thinking Industries BioEnterprise Flocel, Inc. NAMSA (North American Stress Engineering Services, Inc. BioLOGIC Corp., LLC Fort Washington Capital Science Association) Superior Scientific Ltd. BioMedical Research Associates, Inc. Partners Group NanoLogix, Inc. SYMARK LLC Biopack USA Frantz BioMarkers, LLC NeoMed Technologies, Inc. Synapse Biomedical, Inc. BioStorage Technologies Freedom Meditech, Inc. NEOUCOM Syncro Medical Innovations, Inc. Bricker and Eckler, LLP Frost Brown Todd LLC NitAn BioTech LLC Taft, Stettinius & Hollister LLP Britton-Gallagher & Associates, Inc. Future Path Medical, LLC NorTech Taylor Search Partners Business Wire Gallagher & Dawsey Co., LPA North Coast Clinical Laboratory, Inc. TeamNEO Butler Tech Ganeden Biotech, Inc. Oakwood Laboratories, LLC TechColumbus Calfee, Halter & Griswold LLP Gebauer Company Ohio Chamber of Commerce The Anson Group Camargo Pharmaceutical Services Giraffe, Inc. Ohio Supercomputer Center The Blackwell Hotel CardioInsight Technologies Girindus America, Inc. OhioHealth Research and Innovation The Krill Co., Inc. CARON Products & Services, Inc. Global Recruiters of Institute The Ohio Capital Fund Cellular Technology Ltd. Cleveland-Westside OncoImmune Thompson Hine LLP ChanTest Corporation Greater Cincinnati Chamber Opticon Medical Traycer Diagnostic Systems, Inc. Charter Life Sciences of Commerce Orbital Research Triathlon Medical Venture Chateaux Software Greater Cincinnati Tech OrthoHelix Surgical Designs, Inc. Partners, LLC Chubb Group of Insurance Prep Consortium Performance Validation Ulmer Berne, LLP Companies Hahn Loeser & Parks, LLP Pfizer UniClean CID Capital Hicks Partners, LLC PhageVax, Inc. USB Corporation Cincinnati Sub-Zero Products, Inc. Highbridge Associates LLC PharmaForce, Inc. Vertebration CincyTechUSA Hill Top Research Phylogeny, Inc. VWR International Cleveland Medical Devices, Inc. Hybrid Marketing Plastic Moldings Company LLC Ward Engineering, Inc. Cleveland State University Hylant Group Polymer Concepts, Inc. Warren County Career Center CleveX, Inc. Hyper Tech Research, Inc. Porter, Wright, Morris & Arthur Wood, Herron & Evans, L.L.P. Clinical Research Consultants ICON Medical Corporation Praxair Distribution, Inc. Wright Brothers, Inc. Clinical Research Management, Inc. IKOtech, LLC Pressure Biosciences, Inc. X2 Medical Media, A Division of Cognitive Pharmaceuticals, Ltd. Imalux Corporation Prologue Research International, Inc. Stevens Baron Communications, Inc. Columbus Chamber of Commerce ImprovEdge, LLC QTest Labs xi Technology Columbus Nanoworks Infosight Corporation RadioCarb Genetics AE • 33 Bridging the Gap Between Research and Commercialization

Medical device development and contract manufacturing ISO 9001 and ISO 13485 FDA GMP Compliant Contact Bill Evans: 800.321.9348 ext. 114

www.gebauer.com

BioScience MART

SMALL SPACE, BIG MESSAGE To reach bioscience researchers, funding partners, students, and organizations large and small, put the BioScience Mart to work for you. Contact: Jim O’Hare, Publisher +1.614.448.5133 [email protected] www.ohiobiomagazine.com

34 • AE AE • 35